Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
NCT01026610
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
115
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Hepatitis B
Interventions
DRUG:
LB80380 90 mg
DRUG:
LB80380 150 mg
DRUG:
entecavir 0.5 mg
Sponsor
LG Life Sciences